$PepGen(PEPG.US)
PIPELINE, FINANCIALS & PRICE OUTLOOK
PepGen’s 5 mg/kg Phase 2 FREEDOM2-DM1 cohort showed the drug was generally well tolerated, while early results suggested potential clinical benefit.
However, the mixed efficacy data disappointed investors and triggered a sharp selloff in March. The US portion of the trial remains under a partial FDA hold, while approvals in Australia, South Korea and New Zealand allow the study to continue internationally. Its cash runway extends into the second half of 2027, reducing immediate financing pressure.
Technically, PEPG has stabilised above its $2.33 low and is now testing the $2.50 area. Holding around $2.44–$2.50 would keep the recovery setup intact, while a break above $2.62 could open the door to another leg higher.
For now, the stock remains a recovery story in progress, with the next higher-dose data likely to determine whether this rebound can become more sustainable.